Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva® (Erlotinib) in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue To Smoke After Failure of One or Two Prior Chemotherapy Regimens

NCT00294736 is registered in ClinicalTrials.gov with OSI Pharmaceuticals as lead sponsor.

NCT NCT00294736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00294736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva® (Erlotinib) in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue To Smoke After Failure of One or Two Prior Chemotherapy Regimens
Lead sponsor
OSI Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2005
Completion date
September 30, 2007
Enrollment
57 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc